On balance, these bits tend more to the positive than the negative, including a few positive items about COVID-19. (But then, it seems that most of the news about COVID-19 is on the positive side these days.) We’ll get to COVID at the end of this piece, but first I will report on a recent […]
Articles
We’ve got a new ad today from Stansberry’s Investment Advisory ($49, renews at $199), and it sounds a bit familiar — it’s a pitch for an obesity pill that Dave Lashmet, who now helms that letter, thinks could become the best-selling drug in history. It’s pretty much a global consensus that obesity and Alzheimer’s Disease […]
This is the pitch that sent a bucketful of questions heading our way yesterday: “Last Week’s Major FDA Announcement Officially Kick-started a Massive Opportunity “A disease that 42% of Americans suffer from can now be cured. Our analyst tracked this story from the beginning, and he’s finally breaking his silence to reveal the name of […]
This article was originally posted on August 27, when we first saw these ads circulating… apparently lots of folks missed it, and the ads are running hot and heavy again, so we’re re-posting it here to help answer a flood of new reader questions. The stock teased has popped 40-50% or so on the Stansberry […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. You can see all of his articles archived here. Enjoy!] CoLucid Pharmaceuticals, which recently moved from Durham, NC, to Cambridge, MA, plans an initial public offering. Recent news suggests the […]
“I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.” — Oliver Wendell Holmes, M. D., Professor of Medicine , Harvard “With all his conscience and one eye askew, So false he […]
The Zed Files[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
Today the pitch that’s been catching my eye is from Mitchell Clark for his Biotech Breakthrough Stock Report — we haven’t covered this newsletter before, but we have certainly covered teaser spiels from Mitchell Clark’s wide variety of Lombardi-published newsletters in the past (before he was a biotech expert this week, he was a bible […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. His topics, words and opinions are his own. Enjoy!] It’s the second reel of conspiracy film Shooter, and Mark Wahlberg, whom government schemers are trying to frame for assassination, has just been shot twice. In the back of a stolen FBI car, […]
[ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
This is all hush-hush, you understand — I’m taking terrible risks by just writing to you today. And my intrepid readers, members of the resistance, have also pushed the limits in sharing this news. The ad makes this very clear — it came with the subject line, “WARNING! Do Not Share, Do Not Forward” But […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
NVO has been a good investment over the years. Collect the dividends, albeit small, in the mean time until FDA approval...
I've been burned by two of his picks in the past, Rhythm Pharmaceuticals (RYTM) and Esperion Therapeutics (ESPR). Both h...